3200 Lakeside Dr.
Santa Clara
CA
95054
USA
(408) 845-3000
Related Content
November 10, 2009 – The latest data from seven studies focused on the treatment of peripheral arterial disease (PAD) ...
November 10, 2009
November 3, 2009 – Abbott yesterday said both the XIENCE PRIME Everolimus-Eluting Coronary Stent System and the XIENCE V ...
November 03, 2009
October 8, 2009 – The primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study ...
October 08, 2009
October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled in the ...
October 06, 2009
September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT ...
September 30, 2009September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which ...
September 22, 2009
Feature | Dave Fornell
Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high ...
September 17, 2009
Feature | Stents Bifurcation| Dave Fornell
Stenting of lesions at coronary vessel bifurcations is one of the most challenging percutaneous interventions, along ...
September 17, 2009
Feature | Dave Fornell
Over the past year several new drug-eluting stents (DES) stents have been released and SYNTAX trial data proved DES ...
September 17, 2009
Feature | Stents Bioresorbable| Dave Fornell
Metal stents are foreign objects that can irritate vessels and cause stent thrombosis, prevent vessel remodeling ...
September 17, 2009